<DOC>
	<DOCNO>NCT00804856</DOCNO>
	<brief_summary>The trial perform two part , phase I part phase IIa part . In phase I part trial , BI 6727 investigate monotherapy combination low dose cytarabine ( LD-Ara-C ) patient relapsed/refractory AML eligible intensive treatment . The dose BI 6727 escalate determine maximum tolerate dose ( MTD ) BI 6727 monotherapy BI 6727 combination LD-Ara-C AML patient . In phase IIa part , combination BI 6727 MTD LD-Ara-C LD-Ara-C monotherapy investigate explore efficacy combination schedule comparison LD-Ara-C monotherapy previously untreated AML patient eligible intensive treatment .</brief_summary>
	<brief_title>Phase I/IIa Trial Investigate BI 6727 ( Volasertib ) Monotherapy Combination With Cytarabine Acute Myeloid Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion criterion : Male female adult relapsed/refractory AML ineligible intensive treatment ( phase I part ) Male female adult previously untreated AML ineligible intensive treatment ( phase IIa part ) Confirmed diagnosis AML accord WHO definition ( except acute promyelocytic leukaemia , APL ) Patient eligible LDAraC treatment Life expectancy &gt; 3 month Eastern cooperative oncology group ( ECOG , R010787 ) performance score &lt; =2 screen Signed write informed consent consistent international conference harmonisation , good clinical practice ( ICHGCP ) local legislation Exclusion criterion : Previously untreated AML ( phase I part ) Relapsed treatment refractory AML ( phase IIa part ) Patient APL ( AML subtype M3 accord FrenchAmericanBritish ( FAB ) classification ) Hypersensitivity one trial drug excipients Other malignancy require treatment Symptomatic central nervous system involvement Clinically relevant QT prolongation ( e.g . long QT syndrome , QTcF &gt; 470 m ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( ULN ) , AST ALT great 5 time ULN case know leukaemia liver involvement Prothrombin time ( PT ) &gt; 1.5 x ULN subject therapeutic vitamin K antagonist ( phenprocoumon , warfarin ) Bilirubin great 1.5 mg/dl ( &gt; 26 mcmol/L ) Serum creatinine great 2.0 mg/dl Concomitant intercurrent illness , would compromise evaluation efficacy safety trial drug , e.g . active severe infection , unstable angina pectoris , cardiac arrhythmia severe heart failure/cardiac insufficiency . Psychiatric illness social situation would limit compliance trial requirement Concomitant therapy , consider relevant evaluation efficacy safety trial drug Contraindications cytarabine treatment accord SPC Female patient childbearing potential sexually active unwilling use medically acceptable method contraception trial , i.e . combination two form effective contraception ( hormonal contraception , intrauterine device , condom spermicide , etc. ) . Male patient partner childbearing potential unwilling use condom combination second medically acceptable method contraception trial Pregnant nursing female patient Patient unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>